3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Endometrial Neoplasms
2
Uterine Prolapse
1
Uterine Cervical Neoplasms
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Menstruation Disturbances
1
Leiomyoma
1
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
1
Endometriosis
1
Carcinoma, Endometrioid
1
Adenomyosis
1
Interventions
pembrolizumab
14
Cisplatin
13
Specimen Handling
11
Magnetic Resonance Spectroscopy
7
Brachytherapy
7
Bevacizumab
7
Radiotherapy
6
atezolizumab
5
Platinum
5
Paclitaxel
5
Nivolumab
5
Human Papillomavirus DNA Tests
5
Gemcitabine
5
Colposcopy
5
Carboplatin
5
Blood Specimen Collection
5
Radiation
4
Fulvestrant
4
lenvatinib
3
Surveys and Questionnaires
3
Radiation Dose Hypofractionation
3
Drug Therapy
3
Biopsy
3
1,2-diaminocyclohexaneplatinum II citrate
3
zimberelimab
2
tisotumab vedotin
2
spartalizumab
2
palbociclib
2
camrelizumab
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Hysterectomy
×
90 days
×
Clear all
NCT07120945
2026-06-02
Embrace Gyn
Medtronic - MITG
Phase NA
Active not recruiting
70 enrolled